Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

CDNA INVESTORS: July 22, 2022 Filing Deadline in Securities Class Action – Contact Lieff Cabraser

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of CareDx, Inc. (“CareDx” or the “Company”) (Nasdaq: CDNA) from February 24, 2021 through May 5, 2022, inclusive (the “Class Period”).

If you purchased CareDx common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than July 22, 2022. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

CareDx investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here, text or email investorinfo@lchb.com, or call Sharon M. Lee of Lieff Cabraser at 1-800-541-7358.

Background on the CareDx Securities Class Litigation

CareDx is a San Francisco-based company that sells diagnostic services and products to organ transplant recipients.

The action alleges that, throughout the Class Period, CareDx misled investors and/or failed to disclose that: (1) defendants had engaged in a variety of improper and illegal schemes to inflate revenue and demand for testing services; (2) these practices subjected the Company to an undisclosed risk of regulatory scrutiny; and (3) these practices artificially inflated the revenue reported from CareDx’s testing services throughout the Class Period.

On October 28, 2021, CareDx disclosed that it was subject of at least three government investigations (by the U.S. Department of Justice, the Securities Exchange Commission, and a state regulatory agency), concerning the Company’s business practices related to its kidney testing and phlebotomy services, as well as its accounting and public reporting practices. On this news, the price of CareDx shares dropped $19.34, or 27.5%, from a closing price of $70.34 per share on October 28, 2021, to close at $51.00 per share on October 29, 2021, on extremely heavy trading volume.

On April 15, 2022, CareDx’s former Head of Community Nephrology, Dr. Michael Olymbios, sued the Company, alleging, among other things, that the Company had “engaged in various forms of clinical and marketing schemes in an effort to justify [CareDx product] AlloSure’s use, even when that use lacked clinical support and fell outside of the conditional approval extended to it [by Medicare].” On this news, the price of CareDx stock fell $2.86, or 8.1 %, from a closing price of $35.41 on the previous trading day, April 14, 2022, to close at $32.55 per share on the next trading day of April 18, 2022.

On May 5, 2022, CareDx announced that the Company’s testing service revenue fell significantly short of analysts’ expectations, and that average sales price had declined by approximately 4.9% compared with the final quarter of 2021. On this news, the price of CareDx stock dropped $5.88, or 18.6%, from a closing price of $31.66 per share on May 5, 2022, to close at $25.87 per share on May 6, 2022.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Munich, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years. Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm’s “laser focus” and noting that our firm routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.” Benchmark Litigation has named Lieff Cabraser one of the “Top 10 Plaintiffs’ Firms in America.”

For more information about Lieff Cabraser and the firm’s representation of investors, please visit https://www.lieffcabraser.com/securities.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

CDNA INVESTORS: July 22, 2022 Filing Deadline in Securities Class Action – Contact Lieff Cabraser

Contacts

Source/Contact for Media Inquiries Only

Sharon M. Lee

Lieff Cabraser Heimann & Bernstein, LLP

Telephone: 1-800-541-7358

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.